Risk Warning & Pitfall Avoidance: Glucagon Application Scope Pitfalls in Peptide Therapy
Title: Risk Warning & Pitfall Avoidance: Glucagon Application Scope Pitfalls in Peptide Therapy Abstract: Glucagon, a 29-amino acid peptide, primarily functions to elevate blood glucose via hepatic glycogenolysis and gluconeogenesis. In peptide therapy, its application scope is often misapplied for weight loss or muscle gain, leading to severe hypoglycemic rebound or nausea. Market trends show a 12.3% CAGR for glucagon-like peptides, yet brand comparison reveals purity variances (e.g., 98% vs. 99.5%) impacting stability. Technical pitfalls include short half-life (3-6 min) requiring micro-dosing pumps. Product parameter analysis highlights pH sensitivity (optimal 2.5-3.0). Industry data from 2023 indicates 34% of adverse events stem from off-label use. Selecting GMP-certified factories with HPLC purity reports is critical. Logistics require cold chain (2-8°C) to avoid aggregation. Avoid brands lacking third-party COA; prioritize lyophilized forms for longer shelf life.